Christina Greenwood

Christina Greenwood

Auto-generated profile, based on publicly available information

Christina Greenwood

Postgraduate Medical Institute, Faculty of Medical Science, Anglia Ruskin University, Chelmsford, Essex, UK

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2015 in Biomolecular Detection and Quantification
Verified
Journal Article
Open access
CGChristina Greenwood
Christina Greenwood
DRDavid Ruff
David Ruff
SKSara Kirvell
Sara Kirvell
GJGemma Johnson
Gemma Johnson
HDHarvinder S. Dhillon
Harvinder S. Dhillon
SBStephen Bustin
Stephen Bustin
Proximity assays are immunohistochemical tools that utilise two or more DNA-tagged aptamers or antibodies binding in close proximity to the same protein or protein complex. Amplification by PCR or isothermal methods and hybridisation of a labelled probe to its DNA target generates a signal that enables sensitive and robust detection of proteins, protein modifications or protein-protein interactions. Assays can be carried out in homogeneous or solid phase formats and in situ assays can visualise single protein molecules or complexes with high spatial accuracy. These properties highlight the potential of proximity assays in research, diagnostic, pharmacological and many other applications that require sensitive, specific and accurate assessments of protein expression.

1 June 2012 in Journal of Proteomics
Verified
Journal Article
Closed access
CGChristina Greenwood
Christina Greenwood
GMGergana Metodieva
Gergana Metodieva
KAKhalid Al-Janabi
Khalid Al-Janabi
BLBerthold Lausen
Berthold Lausen
LALouise Alldridge
Louise Alldridge
MMMetodi V Metodiev
Metodi V Metodiev

1 January 2015 in Clinical Chemistry
Verified
Journal Article
Closed access
PDF file
SBStephen Bustin
Stephen Bustin
HDHarvinder S Dhillon
Harvinder S Dhillon
SKSara Kirvell
Sara Kirvell
CGChristina Greenwood
Christina Greenwood
MPMichael Parker
Michael Parker
TNTania Nolan
Tania Nolan
BACKGROUND: The reverse transcription (RT) of RNA to cDNA is a necessary first step for numerous research and molecular diagnostic applications. Although RT efficiency is known to be variable, little attention has been paid to the practical implications of that variability. METHODS: We investigated the reproducibility of the RT step with commercial reverse transcriptases and RNA samples of variable quality and concentration. We quantified several mRNA targets with either singleplex SYBR Green I or dualplex probe-based reverse transcription real-time quantitative PCR (RT-qPCR), with the latter used to calculate the correlation between quantification cycles (Cqs) of mRNA targets amplified in the same real-time quantitative PCR (qPCR) assay. RESULTS: RT efficiency is enzyme, sample, RNA concentration, and assay dependent and can lead to variable correlation between mRNAs from the same sample. This translates into relative mRNA expression levels that generally vary between 2- and 3-fold, although higher levels are also observed. CONCLUSIONS: Our study demonstrates that the variability of the RT step is sufficiently large to call into question the validity of many published data that rely on quantification of cDNA. Variability can be minimized by choosing an appropriate RTase and high concentrations of RNA and characterizing the variability of individual assays by use of multiple RT replicates.

1 August 2007 in Complementary Therapies in Clinical Practice
Verified
Journal Article
Closed access
AVA.J. Mc Vicar
A.J. Mc Vicar
CGC.R. Greenwood
C.R. Greenwood
FFF. Fewell
F. Fewell
VDV. D’aRcy
V. D’aRcy
SCS. Chandrasekharan
S. Chandrasekharan
LAL.C. Alldridge
L.C. Alldridge

8 February 2008 in Journal of Proteome Research
Verified
Journal Article
Closed access
LALouise Alldridge
Louise Alldridge
GMGergana Metodieva
Gergana Metodieva
CGChristina Greenwood
Christina Greenwood
KAKhalid Al-Janabi
Khalid Al-Janabi
LTLaura Thwaites
Laura Thwaites
MMMetodi V Metodiev
Metodi V Metodiev

25 April 2016 in Advanced Healthcare Materials
Verified
Journal Article
Open access
PDF file
BOBasmah A. Othman
Basmah A. Othman
CGChristina Greenwood
Christina Greenwood
AAAyman F. Abuelela
Ayman F. Abuelela
ABAnil A. Bharath
Anil A. Bharath
SCShu Chen
Shu Chen
APAlexandra E. Porter
Alexandra E. Porter
ZnO nanoparticles (NPs) are reported to show a high degree of cancer cell selectivity with potential use in cancer imaging and therapy. Questions remain about the mode by which the ZnO NPs cause cell death, whether they exert an intra‐ or extracellular effect, and the resistance among different cancer cell types to ZnO NP exposure. The present study quantifies the variability between the cellular toxicity, dynamics of cellular uptake, and dissolution of bare and RGD (Arg‐Gly‐Asp)‐targeted ZnO NPs by MDA‐MB‐231 cells. Compared to bare ZnO NPs, RGD‐targeting of the ZnO NPs to integrin αvβ3 receptors expressed on MDA‐MB‐231 cells appears to increase the toxicity of the ZnO NPs to breast cancer cells at lower doses. Confocal microscopy of live MDA‐MB‐231 cells confirms uptake of both classes of ZnO NPs with a commensurate rise in intracellular Zn2+ concentration prior to cell death. The response of the cells within the population to intracellular Zn2+ is highly heterogeneous. In addition, the results emphasize the utility of dynamic and quantitative imaging in understanding cell uptake and processing of targeted therapeutic ZnO NPs at the cellular level by heterogeneous cancer cell populations, which can be crucial for the development of optimized treatment strategies.